Masimo Addresses the Inaccurate and Misleading Claims that Covidien Continues to Make Regarding Nellcor Pulse Oximetry Performance
IRVINE, Calif. - Tuesday, July 14th 2015 [ME NewsWire]
(BUSINESS WIRE)-- Masimo (NASDAQ: MASI), the inventor of measure-through motion and low perfusion pulse oximetry, today renewed its $1,000,000 (USD) performance guarantee that Masimo SET® Pulse Oximetry will outperform all Nellcor (part of Covidien and now Medtronic) pulse oximeters. Under the guarantee, if Masimo SET is proven not to be superior to all Nellcor pulse oximeters, including the three that Covidien announced have received FDA 510(k) clearance with motion claims, Masimo will pay up to $1,000,000 to help a hospital acquire that pulse oximetry.
"As a medical technology company, we believe it is our obligation to be truthful and open in our advertising because ultimately patient care is at issue. We continue to be perplexed by the misleading marketing tactics of our competitor," stated Joe Kiani, Founder and CEO of Masimo. “We are concerned that customers may be misled and we hope our guarantee will cause them to question what they are being told and evaluate the performance of the technologies for themselves.”
In addition to renewing the $1 million guarantee, Masimo has updated its website to respond to each of the inaccurate and misleading claims in detail: http://www.masimo.com/nellcorfiction/
Masimo makes four promises to every hospital that to date, Covidien has not been willing to make:
We will demonstrate the superior pulse oximetry performance of Masimo SET® over Nellcor in a side-by-side comparison.
We will provide independent and objective scientific evidence of Masimo SET® superiority over Nellcor, as well as the evidence demonstrating Masimo SET® helps clinicians improve clinical and financial outcomes.
We strongly encourage scientific side-by-side evaluations of Masimo SET® and Nellcor pulse oximetry in challenging conditions with automated data collection.
We are so confident that an objective comparison will reveal the clinical superiority of Masimo SET®, we continue to offer a $1,000,000 performance guarantee.
Please note: This offer is available only to hospitals whose goal is to upgrade their pulse oximetry hospital-wide to the new standard. Important details, conditions, and qualifications for the challenge are available at http://www.masimo.com/1millionrules.htm.
@MasimoInnovates | #Masimo
About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to help clinicians detect life-threatening events. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com. @MasimoInnovates
Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors related to MightySat, including our belief in the breakthrough ability of Masimo SET® pulse oximetry to measure-through motion and low perfusion; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation.
Contacts
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com
Permalink: http://me-newswire.net/news/15130/en
IRVINE, Calif. - Tuesday, July 14th 2015 [ME NewsWire]
(BUSINESS WIRE)-- Masimo (NASDAQ: MASI), the inventor of measure-through motion and low perfusion pulse oximetry, today renewed its $1,000,000 (USD) performance guarantee that Masimo SET® Pulse Oximetry will outperform all Nellcor (part of Covidien and now Medtronic) pulse oximeters. Under the guarantee, if Masimo SET is proven not to be superior to all Nellcor pulse oximeters, including the three that Covidien announced have received FDA 510(k) clearance with motion claims, Masimo will pay up to $1,000,000 to help a hospital acquire that pulse oximetry.
"As a medical technology company, we believe it is our obligation to be truthful and open in our advertising because ultimately patient care is at issue. We continue to be perplexed by the misleading marketing tactics of our competitor," stated Joe Kiani, Founder and CEO of Masimo. “We are concerned that customers may be misled and we hope our guarantee will cause them to question what they are being told and evaluate the performance of the technologies for themselves.”
In addition to renewing the $1 million guarantee, Masimo has updated its website to respond to each of the inaccurate and misleading claims in detail: http://www.masimo.com/nellcorfiction/
Masimo makes four promises to every hospital that to date, Covidien has not been willing to make:
We will demonstrate the superior pulse oximetry performance of Masimo SET® over Nellcor in a side-by-side comparison.
We will provide independent and objective scientific evidence of Masimo SET® superiority over Nellcor, as well as the evidence demonstrating Masimo SET® helps clinicians improve clinical and financial outcomes.
We strongly encourage scientific side-by-side evaluations of Masimo SET® and Nellcor pulse oximetry in challenging conditions with automated data collection.
We are so confident that an objective comparison will reveal the clinical superiority of Masimo SET®, we continue to offer a $1,000,000 performance guarantee.
Please note: This offer is available only to hospitals whose goal is to upgrade their pulse oximetry hospital-wide to the new standard. Important details, conditions, and qualifications for the challenge are available at http://www.masimo.com/1millionrules.htm.
@MasimoInnovates | #Masimo
About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to help clinicians detect life-threatening events. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com. @MasimoInnovates
Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors related to MightySat, including our belief in the breakthrough ability of Masimo SET® pulse oximetry to measure-through motion and low perfusion; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation.
Contacts
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com
Permalink: http://me-newswire.net/news/15130/en
No comments:
Post a Comment